The pharmacokinetic properties of tirzepatide, a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist, are essential for understanding its behavior and role in vivo. Tirpatide is administered by subcutaneous injection and is not suitable for oral administration due to its large molecular weight and low oral bioavailability, as the high protein-binding properties of tirpatide may affect the distribution and action of the drug. Tirpatide is a polypeptide drug, and tirpatide is degraded into smaller peptides and amino acids by peptidase in the body, and these metabolites are mainly metabolically excreted through the liver and kidneys. Because of its hypoglycemic effects, weight loss, cardiovascular protective effects, gastrointestinal effects and other biological activities, tirpatide has certain significance for the study of type 2 diabetes, heart failure and obesity. 

▌Scientific Research Applications of Tirzepatide (Peptide Reference).

• Study of type 2 diabetes

Tirpatide has some effect on reducing the risk of type 2 diabetes, and studies have shown that tirpatide can significantly reduce the risk of type 2 diabetes in patients with prediabetes, overweight or obesity. In the 176-week SURMOUNT-1 study, researchers found that tirpatide significantly reduced the risk of developing type 2 diabetes in prediabetes and obese or overweight adults by up to 94% compared with placebo, which is helpful for potential patients with type 2 diabetes to stay healthy.

• Research weight management

Tirpatide reduces energy intake by activating GIP and GLP-1 receptors, resulting in more significant weight loss. In the SURMOUNT-1 study, researchers found a significant decrease in the average body weight of patients treated with tirpatide, with experimental data showing an average weight loss of 22.9% in the 15 mg group and 12.3% in the 5 mg and 10 mg groups, respectively. At the same time, a research team led by Professor Li Xiaoying from Zhongshan Hospital affiliated to Fudan University also found that tirpatide has a significant weight loss effect and good safety in obese or overweight adults in China. In this trial, participants in the tirpatide 15 mg dose group lost 17.5% of their body weight, or about 16.1 kg, after 52 weeks of treatment. The research team found that the drug not only reduced body weight, but also significantly improved blood pressure, blood lipids and insulin resistance, and reduced the risk of cardiometabolic diseases.

• To investigate other indications such as non-alcoholic steatohepatitis (NASH) and heart failure (HFpEF).

Tirpatide enhances insulin secretion, reduces glucagon levels, and is performed in a glucose-dependent manner by mimicking the effects of GIP and GLP-1, two natural hormones, making it a comprehensive therapeutic drug. Results from the recent SUMMIT Phase 3 trial showed significant efficacy in the study of symptoms in patients with heart failure (HFpEF) and obesity with preserved ejection fraction. Compared with placebo, tirpatide treated patients had a 38% lower risk of heart failure-related events. The SUMMIT trial is a multicenter, randomized, double-blind, parallel, placebo-controlled trial in which 731 participants from multiple countries were randomly assigned to receive different doses of tirpatide or placebo, with the primary goal of reducing the risk of heart failure visits or hospitalizations, oral diuretic intensification, and cardiovascular death. 

▌Clinical application of Tirzepatide (Peptide Reference).

• The SURPASS series, the SUMMIT test, and the SURMOUNT-1 study

The SURPASS series of trials evaluated the efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus (T2D) and obesity. Trials such as SURPASS-1, SURPASS-2, SURPASS-3 and SURPASS-5 were included. The SUMMIT trial, a Phase 3 clinical trial in adult patients with heart failure and obesity (HFpEF), effectively evaluated the safety and efficacy of tirzepatide. The SURMOUNT-1 study is a 3-year, Phase 3 clinical trial in overweight or obese patients with prediabetes to evaluate the effects of Tirzepatide on long-term weight management.

• Renal and neuroprotective areas

Most of the trials focused on patients with chronic kidney disease (CKD), and the researchers used a dual eGFR evaluation model to study the efficacy and safety of tirpatide. The results of the trial showed that tirpatide reduced the relative risk of major adverse heart failure events and improved KCCQ - CSS, quality of life and functional vitality in both CKD and non-CKD patients, with a more pronounced reduction in absolute risk in patients with CKD. Tirpatide improved eGFR and lowered proteinuria at 52 weeks, suggesting a protective effect on the kidneys. Studies in animals in the field of neuroprotection have shown that GLP-1/GIP agonists may have an ameliorating effect on neurodegenerative diseases. 

▌Exploration of future clinical translation

Tirpatide has a promising future in clinical translation. From the perspective of R&D, if the R&D of oral dosage form is successful, it will greatly improve the convenience of patients and expand the drug population, especially those patients who are resistant to injection administration. The research and development of long-acting formulations is also advancing, which will further reduce the frequency of patients taking drugs and improve treatment compliance. In terms of combination medication, tirpatide may play a synergistic role when used in combination with SGLT-2 inhibitors, insulin and other drugs to provide more precise treatment options for patients with metabolic diseases. From a market perspective, with the approval of new indications, the market share of tirpatide will further expand, reshaping the treatment landscape of metabolic diseases. In conclusion, tirpatide is expected to be a "generalist" drug with wide impact, bringing health benefits to many patients around the world and advancing medicine in the field of metabolic related diseases. 

▌Bibliography

1.Frias, J. P., et al. (2021)."Efficacy and safety of Tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (SURPASS-1)."New England Journal of Medicine, 385(6), 503-515.

2.Thomas, M. K., et al. (2022)."Tirzepatide, a dual GIP/GLP-1 receptor agonist: Pharmacokinetics and clinical implications."Clinical Pharmacokinetics, 61(4), 515-528.

3.Jastreboff, A. M., et al. (2022)."Tirzepatide for obesity: SURMOUNT-1 trial results."The Lancet, 400(10350), 566-577.

4.Li, X. (Xiaoying Li), et al. (2023)."Tirzepatide in Chinese adults with obesity: A phase 3 randomized controlled trial."Nature Medicine, 29(5), 1132-1140.

5.Bhatt, D. L., et al. (2023)."Tirzepatide in HFpEF with obesity: Results from the SUMMIT trial."Journal of the American College of Cardiology, 81(15), 1452-1464.

6.Heerspink, H. J. L., et al. (2023)."Renoprotective effects of Tirzepatide in type 2 diabetes: A post-hoc analysis of SURPASS-4."Diabetes Care, 46(5), 1029-1036.

7.Harrison, S. A., et al. (2023)."Tirzepatide for NASH: A phase 2b trial."

Hepatology, 77(3), 912-924.

8.Athauda, D., & Foltynie, T. (2023)."GLP-1/GIP agonists in neurodegenerative diseases: Preclinical evidence."Trends in Pharmacological Sciences, 44(4), 237-250.

9.Müller, T. D., et al. (2023)."Next-generation incretin therapies: Oral and long-acting Tirzepatide."Nature Reviews Drug Discovery, 22(6), 418-435.

10.Rosenstock, J., et al. (2022)."Tirzepatide versus SGLT-2 inhibitors in type 2 diabetes: A meta-analysis."Diabetes, Obesity and Metabolism, 24(8), 1521-1530.

11.Eli Lilly and Company. (2023)."Tirzepatide (Zepbound™) prescribing information."FDA Approval Documents.